Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CM-101 · 1 trial · 3 indications
Incidence and characteristics of adverse events (AEs) occurring following single subcutaneous doses of CM-101
Maximum CM-101 plasma concentration (Cmax)
Time to Cmax (tmax)
Area under the curve (AUC) to the final concentration ≥ limit of quantitation (LOQ), AUC(0-t) and to infinity AUCinf
Terminal elimination rate constant (λz)
Terminal elimination half-life (T½)
| Arm | Type | Description |
|---|---|---|
| Anti-human CCL24 monoclonal antibody (CM-101) | EXPERIMENTAL | Single 5 mg/kg of CM-101, Subcutaneous administration |
| Placebo | PLACEBO_COMPARATOR | Placebo : Subcutaneous administration |
| Name | Type | Description |
|---|---|---|
| CM-101 | DRUG | Anti-human CCL24 monoclonal antibody (CM-101) |
| Placebo | DRUG | Placebo Comparator |
Inclusion Criteria: 1. Subjects must provide written informed consent prior to participating in the study. 2. Considered healthy by the Investigator as defined by no clinically relevant abnormalities identified by a detailed medical history, full physical examination, 12-lead ECG, and clinical labo...
CM-101 is an investigational small molecule developed by Chemomab Therapeutics Ltd. It is being studied as a treatment for medical conditions involving inflammatory and fibrotic mechanisms, including nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), and systemic sclerosis (SSc). CM-101 is in Phase 1 clinical development.
CM-101 is being developed as a potential treatment for nonalcoholic steatohepatitis (NASH), a liver condition characterized by inflammation and fibrosis. It is also being studied in primary sclerosing cholangitis and systemic sclerosis. CM-101 remains investigational and has not been approved for any indication.
CM-101 targets CCL24, a protein that plays a role in inflammatory and fibrotic processes. By targeting CCL24, CM-101 is designed to address conditions involving these mechanisms, such as nonalcoholic steatohepatitis, primary sclerosing cholangitis, and systemic sclerosis.
CM-101 is being developed by Chemomab Therapeutics Ltd., a biotechnology company. Chemomab Therapeutics trades on the Nasdaq under the ticker symbol CMMB.
CM-101 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency for any indication.
CM-101 has been evaluated in a completed Phase 1 trial, NCT06037577, which studied subcutaneous doses of CM-101 in healthy male subjects. The trial enrolled 8 participants and was conducted in Israel. It was randomized, double-blind, and placebo-controlled.